Summary of Significant Accounting Policies (Details Narrative) - USD ($)
6 Months Ended
Aug. 31, 2021
Aug. 31, 2020
Research and development expenses $ 13,922,632 $ 267,743
Restricted Stock Units    
Antidilutive securities 4,170,278 4,313,750
Warrants    
Antidilutive securities 11,684,418 4,884,331
Stock Options [Member]    
Antidilutive securities 1,587,081 1,587,081